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Motoric cognitive risk syndrome
Multicountry prevalence and dementia risk
ABSTRACT
Objectives: Our objective is to report prevalence of motoric cognitive risk syndrome (MCR), a
newly described predementia syndrome characterized by slow gait and cognitive complaints, in
multiple countries, and its association with dementia risk.
Methods: Pooled MCR prevalence analysis of individual data from 26,802 adults without demen-
tia and disability aged 60 years and older from 22 cohorts from 17 countries. We also examined
risk of incident cognitive impairment (Mini-Mental State Examination decline $4 points) and
dementia associated with MCR in 4,812 individuals without dementia with baseline Mini-
Mental State Examination scores $25 from 4 prospective cohort studies using Cox models
adjusted for potential confounders.
Results: At baseline, 2,808 of the 26,802 participants met MCR criteria. Pooled MCR prevalence
was 9.7% (95% confidence interval [CI] 8.2%–11.2%). MCR prevalence was higher with older
age but there were no sex differences. MCR predicted risk of developing incident cognitive
impairment in the pooled sample (adjusted hazard ratio [aHR] 2.0, 95% CI 1.7–2.4); aHRs were
1.5 to 2.7 in the individual cohorts. MCR also predicted dementia in the pooled sample (aHR 1.9,
95% CI 1.5–2.3). The results persisted even after excluding participants with possible cognitive
impairment, accounting for early dementia, and diagnostic overlap with other predementia
syndromes.
Conclusion: MCR is common in older adults, and is a strong and early risk factor for cognitive
decline. This clinical approach can be easily applied to identify high-risk seniors in a wide variety
of settings. Neurology® 2014;83:718–726
GLOSSARY
aHR 5 adjusted hazard ratio; CI 5 confidence interval; H-EPESE 5 Hispanic Established Populations for Epidemiologic
Studies of the Elderly; HR5 hazard ratio; InCHIANTI5 Invecchiare in Chianti;MAP5Memory and Aging Project;MCI5mild
cognitive impairment; MCR 5 motoric cognitive risk syndrome; MMSE 5 Mini-Mental State Examination; ROS 5 Religious
Orders Study.
Predementia syndromes based on cognitive tests, biomarkers, or neuroimaging have been pro-
posed to identify dementia risk in older adults,1,2 but have limitations in many settings. For
instance, an estimated two-thirds of persons with dementia live in low- and middle-income
countries where there is often no access to complex neuropsychological testing or neuroimag-
ing.2,3 Hence, there is a need to optimize and increase accessibility of clinical dementia risk
assessments in order to institute preventive measures and curtail health care costs.
There is increasing evidence that gait slowing occurs early in dementia and may precede
declines in cognitive tests.4–6 Hence, incorporating gait into dementia risk assessments is a novel
approach that can be used even in resource poor settings.7 The motoric cognitive risk syndrome
(MCR), a recently described predementia syndrome characterized by cognitive complaints and
slow gait, avoids the need for complex cognitive tests or other burdensome investigations.7,8
Our goal is to report prevalence of MCR in 26,802 older adults from 17 countries. We pre-
dicted that participants with MCR would have higher disease burden and worse cognitive status
than non-MCR participants.8 Older adults with MCR in our validation study8 were at increased
risk of dementia even after accounting for potential confounders and diagnostic overlap with
Authors’ affiliations are listed at the end of the article.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
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mild cognitive impairment (MCI) syndrome.
To further explore this finding, we studied the
association of MCR with risk of cognitive
decline in 4,812 cognitively normal individu-
als without dementia and with Mini-Mental
State Examination (MMSE) scores $25 from
4 well-established cohorts.
METHODS The MCR consortium includes data from 22
cohorts from 17 countries: 7 North American,9–15 6 Euro-
pean,16–19 5 Asian,15,20–22 2 African,15 1 Israel,23 and 1 Australia.24
Sixteen studies were community-based, 4 memory clinics, and 2
recruited from clinic and community. Eligible cohorts contained
baseline information on cognitive complaints, gait speed,
cognitive tests, mobility disability, and dementia. Main features
are summarized in table 1. From 62,215 available individuals, we
excluded 27,882 who were younger than 60 years because our
focus was the geriatric population, and few studies enrolled
younger participants. From the remaining 34,333 participants,
we excluded those missing gait speed (n 5 4,508) and cognitive
complaints (n 5 517). We also excluded 881 participants with
mobility disability (inability to ambulate with or without assistive
devices) and 1,625 with clinically adjudicated dementia at
baseline. Table 1 lists diagnostic procedures in individual
studies. After exclusions, the final sample included 26,802
individuals aged 60 years and older.
Standard protocol approvals, registrations, and patient
consents. The institutional review board of the Albert Einstein
College of Medicine approved this analysis. Each site obtained
approval from their local ethics committee.
MCR. MCR diagnosis builds on MCI criteria,1 and is defined as
presence of cognitive complaints and slow gait in older individ-
uals without dementia or mobility disability.8 Table e-1 on the
Table 1 MCR consortium: Summary of studies, procedures, and tests
Study, inception year No., total/eligible Age range, y Gait assessment Cognitive complaint Dementia diagnosis
Australia (TASCOG), 2005 426/413 61–86 GAITRite GDSa Clinicalb
Belgium, 2010 171/82 62–90 GAITRite Self-report DSM-IVc
Canada, 2007 92/87 63–93 GAITRite Self-report DSM-IV
China (SAGE), 2007 15,050/6,539 60–94 4-m walk Self-report Clinical
France (GAIT), 2009 355/354 63–90 GAITRite Self-report DSM-IV
Ghana (SAGE), 2007 5,858/2,382 60–114 4-m walk Self-report Clinical
India (KES), 2011 391/271 60–94 10-ft walk GDS DSM-IV
India (SAGE), 2007 12,198/3,377 60–105 4-m walk Self-report Clinical
Israel (2 cohorts), 2003 285/224 69–94 10-m walk GDS DSM-IV
786/239 60–90 GAITRite GDS DSM-IV
Italy (InCHIANTI), 1998 1,453/975 60–96 4-m walk Disability Scale DSM-IV
Japan, 2008 591/514 74–95 6-m walk Self-report DSM-IV
Korea (KLoSHA), 2005 1,000/549 65–102 4-m walk Self-report DSM-IV
Mexico (SAGE), 2007 5,448/1,442 60–96 4-m walk Self-report Clinical
Russia (SAGE), 2007 4,947/1,708 60–101 4-m walk Self-report Clinical
South Africa (SAGE), 2007 4,227/1,743 60–113 4-m walk Self-report Clinical
Switzerland, 2007 1,921/344 60–113 GAITRite GDS DSM-IV
United Kingdom, 2007 189/173 61–90 GAITRite GDS DSM-IV
United States (LonGenity, 2006) 852/510 61–94 GAITRite GDS DSM-IV
United States (CCMA), 2011 359/326 65–96 GAITRite GDS and AD8 DSM-IV
United States (MAP), 1997 1,505/1,371 60–100 8-ft walk Self-report DSM-III-R
United States (ROS), 1994 1,061/1,041 62–100 8-ft walk Self-report DSM-III-R
United States (H-EPESE), 1994 3,050/2,138 65–108 9-ft walk IADL Clinical
Abbreviations: AD8 5 cognitive screening instrument; CCMA 5 Central Control of Mobility in Aging; DSM-III-R 5 Diagnostic and Statistical Manual of
Mental Disorders, 3rd edition, revised; DSM-IV 5 Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAIT 5 Gait and Alzheimer Inter-
actions Tracking Study; GDS 5 Geriatric Depression Scale; H-EPESE 5 Hispanic Established Populations for Epidemiologic Studies of the Elderly; IADL 5
Instrumental Activities of Daily Living Scale; InCHIANTI 5 Invecchiare in Chianti; KES 5 Kerala-Einstein study; KLoSHA 5 Korean Longitudinal Study on
Health and Aging; MAP 5 Memory and Aging Project; MCR 5 motoric cognitive risk syndrome; ROS 5 Religious Orders Study; SAGE 5 Study on Global
Ageing and Adult Health; TASCOG 5 Tasmanian Study of Cognition and Gait.
a Cognitive complaint coded present if self-report elicited on cognitive questionnaires or if there was a positive response on the geriatric depression item:
“Do you feel you have more problems with memory than most?”
bClinical diagnosis of dementia at baseline was done by self-report, review of medical history, cognitive testing, and/or clinical interview, followed by
interview of proxy if available.
cDSM-III-R or DSM-IV was done with consensus diagnostic case conference procedures in the individual studies.
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Neurology® Web site at Neurology.org lists tests and procedures in
individual cohorts. Cognitive tests were not used to assign MCR.
Presence of cognitive complaints was ascertained by participant
responses on standardized questionnaires administered by
interviewers (table e-1).8 Informant reports were not used because
no cohort had this as a requirement. Gait speed (cm/s) was
measured quantitatively or timed over a fixed distance. Slow gait
was defined as walking speed 1 SD below age- and sex-specific
means individualized to each cohort (table e-1).8
To account for population and procedural differences, we
examined an alternate MCR definition by deriving global slow
gait cutscores pooling gait data from all sites. We also examined
MCR prevalence in 2,753 individuals (10.2%) from 9 studies
in which gait speed was measured with similar equipment
(GAITRite25; CIR Systems, Inc., Sparta, NJ) (table 1) and walk-
ing protocols.
Other covariates. Scores on tests of global mental status, mem-
ory, attention, executive function, and depressive symptoms in
each cohort were standardized to facilitate comparisons. Because
not all studies diagnosed MCI,1 we classified participants as MCI
if they had cognitive complaints and memory or nonmemory test
scores 1.5 SDs below age- or sex-specific means in each cohort.1
Presence of self-reported vascular diseases (any one of angina,
hypertension, diabetes, and strokes), depression, and arthritis was
recorded. Information on myocardial infarctions, TIA, and Par-
kinson disease was available for ,15% of the sample, and is
not reported.
Cognitive outcomes. Incident cognitive impairment was
defined as a change during follow-up in MMSE scores of $4, a
reliable indicator of significant cognitive decline.26 Four studies
with 4,812 participants with longitudinal data were included.
The Chicago-based Memory and Aging Project (MAP) is a
clinical-pathologic aging study (mean age 79.9 years, 74.0%
women, 93.1% Caucasian, 6.2% African American).14 The
Religious Orders Study (ROS) is also based in Chicago, but
enrolled religious clergy from across the United States (mean
age 75.1 years, 69% women, 91.7% Caucasian, 7.2% African
American).11 The Hispanic Established Populations for
Epidemiologic Studies of the Elderly (H-EPESE) is a representative
sample of community-dwelling Mexican American elderly from 5
southwestern US states (mean age 72.3 years, 56% women).12 The
Invecchiare in Chianti (InCHIANTI) Study is a representative
population-based study in Chianti, Italy (mean age 74.1 years,
55% women).17
Dementia was diagnosed prospectively using individual study
procedures (tables 1 and e-1) in MAP,14 ROS,11 and H-EPESE
cohorts,12 and examined as a secondary cognitive outcome.
Analysis. Random-effects meta-analysis was used to pool
individual and summary estimates. Heterogeneity between
studies was tested using the x2 test and quantified by the I2
statistic. We report MCR prevalence by age and sex.
Associations with 95% confidence intervals (CIs) of MCR with
medical and cognitive variables were examined using linear
regression for continuous variables and logistic models for
binary variables, adjusted for age, sex, and education.
To confirm MCR as a dementia risk factor, we used Cox
models to compute hazard ratios (HRs) with 95% CIs adjusted
for age, sex, education, cohort source, baseline MMSE scores,
and vascular disease for developing cognitive impairment and demen-
tia. All participants were clinically adjudicated to be dementia-free at
baseline using individual study procedures (table 1). In addition, we
excluded participants with MMSE scores ,25. We examined asso-
ciations in the pooled sample using meta-analysis. We conducted
sensitivity analyses to account for early dementia and diagnostic over-
lap with MCI.
RESULTS The ages of the 26,802 participants
ranged from 60 to 114 years (mean 71.6), with
55.7% women, and mean education 6.9 years. Mean
gait speed was 81.8 6 32.7 cm/s. Participants with
MCR had worse performance on all cognitive tests
than participants without MCR (table 2). Partici-
pants with MCR had higher prevalence of vascular
and nonvascular diseases. High education ($12
years) was associated with reduced risk of MCR (esti-
mate 20.47, 95% CI 20.65 to 20.29, p , 0.001).
Older age ($75 years) had a borderline association
(estimate 0.14, 95% CI 20.00 to 0.28, p 5 0.05)
and sex was not associated with MCR (estimate 0.03,
95% CI 20.06 to 0.11, p 5 0.55).
Prevalence. Of the 26,802 participants, 2,808 met
MCR criteria. Pooled MCR prevalence among indi-
viduals aged 60 years and older was 9.7% (95% CI
8.2%–11.2%). Age- and sex-adjusted pooled MCR
prevalence was 9.6% (95% CI 8.7%–10.6%). MCR
prevalence in 6 low- or middle-income countries with
14,011 participants ranged from 5.3% to 15.5%
(figure 1). MCR prevalence was higher in the 8,651
individuals aged 75 years and older (10.6%, 95% CI
9.0%–12.3%) than in the 18,151 individuals aged 60
to 74 years (8.9%, 95% CI 7.1%–10.7%).
Prevalence of MCR was similar in 11,881 men
(9.5%, 95% CI 7.9%–11.1%) and 14,921 women
(9.6%, 95% CI 7.8%–11.3%).
MCR prevalence using alternate criteria (global
slow gait cutscores) was 9.2% (95% CI 7.7%–
11.0%, I2 90.0%). MCR prevalence in 2,753 indi-
viduals with similar GAITRite walking protocols25
was 8.0% (95% CI 5.0%–1.1%, I2 80.1%). MCR
prevalence was similar in the 11 studies that used
similar assessments for gait speed (timed walk) and
cognitive complaint (self-report questionnaire): 9.0%
(95% CI 8.1%–10.7%, I2 65.0%).
Figure 1 shows MCR prevalence in the individual
cohorts (I2 94.2%). The lowest MCR prevalence was
seen in the Australian (2%) and UK (2%) studies that
recruited ambulatory seniors with high walking
speeds.18,24 The highest MCR prevalence was in
French (16%) and Indian (15%) cohorts, which
enrolled seniors with cognitive complaints.19,20 When
these 4 outliers with lowest and highest prevalence
rates were excluded, pooled MCR prevalence was
10.0% (95% CI 8.7%–11.3%). When the Canadian,
French, and Belgian cohorts that only enrolled partic-
ipants with cognitive complaints were excluded,10,19
MCR prevalence was 9.1% (95% CI 7.5%–10.8%).
Cognitive outcomes. Mean follow-up varied from 5.1
to 9.3 years. MCR predicted incident cognitive
720 Neurology 83 August 19, 2014
impairment in all cohorts with adjusted HRs (aHRs)
ranging from 1.48 in the H-EPESE to 2.74 in
InCHIANTI (table 3).
To examine whether MCR mainly identifies indi-
viduals with early dementia, we repeated the analysis
excluding 668 participants who met incident cogni-
tive impairment criteria in the first 3 years. MCR still
predicted incident cognitive impairment in this sub-
group (aHR 1.71, 95% CI 1.31–2.24). MCR also
predicted incident cognitive impairment when the
analysis was restricted to 3,289 participants with base-
line MMSE scores $28 (aHR 1.65, 95% CI 1.36–
2.01). The results were similar in individual cohorts
(data not shown).
While MCR is diagnosed independent of cogni-
tive tests used to define MCI, 39% of individuals
with MCR also met MCI criteria.1 Both MCR
(aHR 1.63, 95% CI 1.39–1.89) and MCI (aHR
1.36, 95% CI 1.19–1.56) predicted cognitive impair-
ment when examined together in the same model.
There were 212 incident dementias in MAP, 265
in ROS, and 417 in H-EPESE. MCR predicted
dementia in MAP (aHR 2.10, 95% CI 1.43–2.09),
ROS (aHR 1.98, 95% CI 1.44–2.74), and H-EPESE
(aHR 1.79, 95% CI 1.31–2.44) cohorts as well as in
the pooled sample (aHR 1.93, 95% CI 1.59–2.35).
MCR was associated with increased risk of Alzheimer
disease dementia11,14,27 in MAP (aHR 2.21, 95% CI
1.49–3.28) and ROS (aHR 1.97, 95% CI 1.41–
2.74) cohorts. There were insufficient cases of vascu-
lar dementia to examine as an outcome. Dementia
subtyping was not done in H-EPESE.
Figure 2A graphically presents risk of incident cog-
nitive impairment over 12 years’ follow-up associated
with MCR (HR adjusted for age, sex, education, and
cohort source 1.69, 95% CI 1.44–1.98), slow gait
alone (aHR 1.40, 95% CI 1.20–1.65), and self-
reported cognitive complaints alone (aHR 1.09,
95% CI 0.94–1.27) compared with healthy controls
with neither subjective cognitive complaints nor slow
gait. Figure 2B shows risk of dementia over 12 years’
follow-up associated with MCR (aHR 2.47, 95% CI
1.93–3.17), slow gait alone (aHR 1.77, 95% CI
1.38–2.27), and cognitive complaints alone (aHR
1.27, 95% CI 0.99–1.63) compared with healthy
controls.
DISCUSSION In this multicountry study of 26,802
older adults, pooled prevalence of MCR was 9.7%.
MCR prevalence was higher in persons aged 75 years
and older, paralleling the greater prevalence of cogni-
tive complaints and dementia in this age segment.
There were no sex differences in MCR prevalence.
Our findings show that MCR criteria can be easily
Table 2 Motoric cognitive risk syndrome (MCR) baseline characteristics
Sample, n MCR No MCR p Value
No. 26,802 2,808 23,994
Age, y 26,802 73.6 6 8.2 71.4 6 7.5 ,0.001
Women, % 26,802 57.0 6 0.5 56.0 6 0.5 0.145
Education, y 25,668 6.2 6 6.0 7.0 6 6.0 ,0.001
Gait speed, cm/s 26,802 47.8 6 20.0 85.8 6 31.5 ,0.001
Medical illness, %
Angina 22,236 16.2 6 3.7 12.1 6 3.3 ,0.001a
Hypertension 26,543 75.9 6 4.3 71.5 6 4.5 ,0.001a
Diabetes 26,429 15.2 6 3.6 11.4 6 3.2 ,0.001a
Strokes 26,458 8.7 6 2.8 4.4 6 2.3 ,0.001a
Depression 26,653 9.0 6 2.9 6.0 6 2.4 ,0.001a
Arthritis 22,690 32.4 6 4.7 26.6 6 4.4 ,0.001a
Cognitive tests, z score
Global mental score 25,828 20.36 6 1.06 0.06 6 0.98 ,0.001a
Memory 22,111 20.29 6 0.97 0.04 6 1.00 ,0.001a
Attention 22,155 20.21 6 1.04 0.04 6 0.98 ,0.001a
Executive function 23,215 20.23 6 0.96 0.04 6 1.00 ,0.001a
Depressive symptoms 8,767 0.38 6 1.14 20.05 6 0.97 ,0.001a
aAdjusted for age, sex, and education.
Values are means 6 SD.
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applied in clinical settings with simple questions
about cognitive complaints and timing gait; 90% of
participants had walking timed over fixed distances
without requiring major resource commitments.
MCR was associated with a 2-fold increased risk of
developing incident cognitive impairment (aHR 2.0)
in 4,812 participants without dementia and MMSE
scores$25, even after accounting for vascular disease
and baseline cognitive status.8 MCR predicted
dementia in our current (aHR 1.9) and previous
(aHR 3.3) analyses.8 MCR was a stronger predictor
of cognitive outcomes than its individual components
of cognitive complaints or slow gait in the current and
previous validation study.8 The association of MCR
with cognitive impairment remained even when the
analysis was conservatively restricted to participants
with baseline MMSE scores $28 or when incident
cognitive impairment cases in the first 3 years were
excluded. These findings support MCR as an early
clinical marker for cognitive decline.
MCR predicted vascular dementia in our valida-
tion cohort.8 However, MCR predicted Alzheimer
disease dementia in more than 2,000 participants
from 2 cohorts in this study.11,14 This finding may
Figure 1 Prevalence of motoric cognitive risk syndrome
Prevalence estimates (ES) for each study are graphically represented by small diamonds and 95% CIs by horizontal bars. Gray boxes surrounding the dia-
monds graphically represent study weighting in the analysis, which is also shown in the last column. The large diamond is the pooled prevalence estimate.
Pooled effect estimate was similar for random- and fixed-effects model. The vertical dotted line represents the prevalence estimates of the pooled result.
CCMA5 Central Control of Mobility in Aging; CI5 confidence interval; MAP5Memory and Aging Project; ROS5 Religious Orders Study; SAGE5 Study on
Global Ageing and Adult Health.
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be explained by the higher frequency of mixed brain
pathology with advancing age.28 Alternatively, Alz-
heimer pathology can manifest in early gait dysfunc-
tion as suggested by reports of gait slowing in the
years leading to MCI.4–6,29 The association of MCR
with clinical dementia subtypes needs to be further
verified. The inverse association noted between edu-
cation and MCR needs further scrutiny to gain in-
sights into potential interventions. Three of 4 cohorts
in the cognitive analysis were from the United States,
as was our initial study.8 While insights into dementia
gained from these 4 well-established cohorts have
been generalizable to other populations,8,11,12,14,25,30
MCR findings should be cross-validated in other
countries.
The gait-based MCR offers several benefits in de-
tecting cognitive risk. Gait speed has a common met-
ric, high reliability between different protocols, and
excellent validity in predicting health out-
comes.12,25,31,32 A universal test or metric is lacking
for cognitive test–based predementia syndromes,
and may account for variance in reported preva-
lence.1,33 Unlike MCR criteria that can be easily
and inexpensively applied, neuropsychological tests
to diagnose MCI or laboratory and imaging tests for
biomarker-based predementia syndromes may not be
practical in many settings.1,2 MCR is diagnosed inde-
pendent of cognitive tests minimizing diagnostic cir-
cularity in using the same test to define predementia
and dementia syndromes.
A key strength is that our study is based on well-
established cohorts with reliable cognitive and motor
protocols from multiple nations, 52% from low- or
middle-income countries. Because MCR is newly
proposed, there are no other comparative studies.8
There are few global studies of predementia syn-
dromes, and fewer still in low- or middle-income
countries.33 A low prevalence of amnestic MCI was
reported in 15,376 seniors from 8 low- or middle-
income countries: from 0.8% in China to 4.3% in
India.33 Lack of specificity in MCI criteria was
proposed to account for the low prevalence.33 MCR
prevalence was higher in the 14,011 participants from
our 6 low- or middle-income countries. HRs for cog-
nitive impairment were similar for MCR and MCI.
To our knowledge, this is one of the largest prev-
alence studies of a predementia syndrome, yet it
shares limitations of prior studies in not being
global.33 While representing all countries may not
be feasible, MCR needs to be examined elsewhere
because etiologies for core criteria such as cognitive
complaints and slow gait might vary regionally. Then
again, modifiable risk factors for cardiovascular dis-
ease and strokes,34,35 major contributors to gait and
cognitive declines, were remarkably consistent glob-
ally. Although detailed vascular or neuroimaging
studies may reveal underlying etiologies for MCR,
resource constraints will not permit screening all pa-
tients with these tests. The MCR approach can help
streamline high-risk individuals for further investiga-
tions, especially in resource-poor settings.
Because the inception of our studies antedated the
MCR concept,8 heterogeneity is not unexpected
given clinical and methodologic diversity. While
some might preclude pooling data due to heteroge-
neity, we believe the summary data provide a global
perspective on MCR. The variance in MCR preva-
lence in our different sites is in accord with the var-
iability in MCI and dementia prevalence globally.1,33
Moreover, our estimates show the same direction of
effect in multiple sites, an equally important consid-
eration in meta-analyses.36 The high agreement in
MCR prevalence defined multiple ways and exclud-
ing subgroups is reassuring. There was no significant
heterogeneity in longitudinal analyses. Reasons for
heterogeneity are not explained by subgroup analyses,
but might include differences in methods. Memory
complaints are subject to cultural bias,33 a limitation
of MCR common with MCI and dementia defini-
tions.1,27 However, exclusion of cohorts that recruited
only participants with memory complaints or restric-
tion to cohorts that used similar cognitive complaint
Table 3 Motoric cognitive risk syndrome and risk of cognitive impairment
Country (study) Eligible sample, n Follow-up, y, mean 6 SD Incident cases, n
Cognitive impairment
Unadjusted HR (95% CI), p value Adjusted HR (95% CI), p value
United States (H-EPESE) 1,562 6.04 6 2.06 826 1.65 (1.30–2.10), ,0.001 1.48 (1.16–1.88), 0.002
United States (MAP) 1,280 5.08 6 3.61 377 1.61 (1.17–2.21), 0.003 1.49 (1.08–2.07), 0.015
United States (ROS) 1,013 9.28 6 5.38 374 2.19 (1.67–2.88), ,0.001 1.90 (1.44–2.51), ,0.001
Italy (InCHIANTI) 700 7.23 6 3.21 180 3.54 (2.05–6.12), ,0.001 2.74 (1.54–4.86), 0.001
Abbreviations: CI 5 confidence interval; H-EPESE 5 Hispanic Established Populations for Epidemiologic Studies of the Elderly; HR 5 hazard ratio;
InCHIANTI 5 Invecchiare in Chianti; MAP 5 Memory and Aging Project; ROS 5 Religious Orders Study.
Associations are reported as HRs with 95% CIs unadjusted as well as adjusted for age, sex, education, baseline Mini-Mental State Examination scores, and
presence of vascular disease. Cognitive impairment was defined as a 4-point or more change in Mini-Mental State Examination scores over follow-up.
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ascertainment did not change the MCR prevalence
estimates. Refinements of cognitive complaint ascer-
tainment should be pursued to increase the specificity
of the MCR criteria.
Given differences in source populations, sample
sizes, and protocols, variability in gait cutscores is
not unexpected. This situation is not unique to gait;
cognitive test norms also vary by population. We used
insular slow gait cutscores in each cohort, reflected in
the relatively narrow MCR prevalence range of 7% to
13% in 17 studies (81% of sample). Furthermore,
MCR prevalence rates were not materially changed
when an alternate secular definition using global slow
gait cutscores was used or when examined in the sub-
group with uniform instrumented gait protocols,
although heterogeneity remained high. However,
global slow gait cutscores or arbitrary cutscores will
not account for regional variations and bias against
the oldest age groups. The slow gait criterion was
age- and sex-adjusted, which accounts for similarity
in the adjusted and unadjusted MCR prevalence. As
is done for cognitive tests, we recommend developing
local slow gait norms.
Gait speed may not be the strongest motoric pre-
dictor of dementia,25 but there is limited information
on comparative predictive validity of other motoric
signs for dementia.8,25 Substituting motoric signs
such as tone or strength for slow gait in MCR did
not improve dementia prediction.8 Gait markers,
such as variability or rhythm, predict declines on spe-
cific cognitive domains.25 The need for instrumenta-
tion will restrict accessibility of these quantitative
markers by nonspecialists or in community settings.7,8
Nonetheless, other motoric markers should be inves-
tigated in research settings to improve MCR defini-
tion to gain insights into early stages of dementia.
Given the scale of data collection and retrospective
design, a more limited analysis than is possible in
single-population studies was done. For instance,
APOE genotype information that may have shed light
on cognitive and gait decline was not available.37,38
Dementia prevalence may be underestimated with
criteria used in our participating studies, particularly
in low- and middle-income countries.3 However,
informant reports and functional scales needed to
apply alternate dementia criteria were not available
in all of our cohorts.3 The agreement in predictive
validity of MCR for cognitive outcomes in different
well-established cohorts and after accounting for early
dementia or overlap with MCI is reassuring.
This multicountry study supports MCR as a high
risk of dementia phenotype that can be easily applied
and identified in a variety of settings by clinicians.
Further validation studies are required so that clini-
cians and researchers may utilize this clinical approach
to improve dementia risk assessments, plan manage-
ment, and develop novel interventions to prevent
cognitive decline worldwide.
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